Dostarlimab Boosts Long-Term Survival in Endometrial Cancer Christos Evangelou, MSc, PhD June 22, 2026

https://www.medscape.com/viewarticle/dostarlimab-boosts-long-term-survival-endometrial-cancer-2026a1000kyu Adding the PD-1 inhibitor dostarlimab to standard chemotherapy provides sustained survival benefits for patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) advanced endometrial cancer, according to updated results from the phase 3 RUBY trial.